Policy & Practice

View the latest content related to this topic

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Michael O'Riordan

May 01, 2025

Slides

See all

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Pratik Sandesara

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Bryan Kindya

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Laura Young

February 28, 2025

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

Presentation Controversies and Advances 2025

The role of double-blind sham-controlled trials in interventional cardiology

Presenter: Rasha Al-Lamee

January 31, 2025

News

See all

News Daily News

Another Win for PREVENT, This Time in Older Adults

By Yael L. Maxwell

May 06, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

By Caitlin E. Cox

May 06, 2025

News Conference News SCAI 2025

Pain in the Neck? Operators Seek Solutions to Lead’s Weighty Toll

By L.A. McKeown

May 05, 2025

News Conference News SCAI 2025

Benefits of TAVI Before Symptom Onset Not Hindered by Age: EARLY TAVR

By L.A. McKeown

May 02, 2025

News Conference News SCAI 2025

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

By L.A. McKeown

May 02, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Policy & Practice

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Slides

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

The Good, the Bad and the Ugly of Clinical Trial Design

The role of double-blind sham-controlled trials in interventional cardiology

News

Another Win for PREVENT, This Time in Older Adults

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Pain in the Neck? Operators Seek Solutions to Lead’s Weighty Toll

Benefits of TAVI Before Symptom Onset Not Hindered by Age: EARLY TAVR

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Policy & Practice

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content